Enablex Related Published Studies
Well-designed clinical trials related to Enablex (Darifenacin)
Time-to-effect with darifenacin in overactive bladder: a pooled analysis. [2011]
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. [2008.11]
Clinical relevance of health-related quality of life outcomes with darifenacin. [2008.07]
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. [2008]
Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. [2007.10]
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. [2006.11]
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. [2006.05]
Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. [2006.01]
Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. [2005.11]
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. [2005.09]
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. [2005.09]
Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. [2005.07]
Increased warning time with darifenacin: a new concept in the management of urinary urgency. [2005.04]
An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. [2005.03]
Assessment of cognitive function of the elderly population: effects of darifenacin. [2005.02]
Well-designed clinical trials possibly related to Enablex (Darifenacin)
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. [2010.07]
Contribution of the M3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed. [2008.08]
Other research related to Enablex (Darifenacin)
Time-to-effect with darifenacin in overactive bladder: a pooled analysis. [2011.12]
Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder. [2011.02]
Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. [2010.07.31]
Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. [2008.12]
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. [2008.11]
Interstitial granulomatous dermatitis associated with darifenacin. [2008.09]
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. [2008.08.11]
A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. [2008.04]
Clinical relevance of health-related quality of life outcomes with darifenacin. [2008.03.04]
The effect of darifenacin on overactive bladders in female and male rabbits. [2008]
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. [2008]
Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. [2007.11]
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. [2007.09]
Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. [2007.03]
Darifenacin: Pharmacology and clinical usage. [2006.11]
Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older Subjects. [2006.08]
The clinical pharmacokinetics of darifenacin. [2006]
Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. [2005.09]
Darifenacin in the treatment of overactive bladder. [2005.07]
Darifenacin in the treatment of overactive bladder. [2005.07]
Darifenacin: another antimuscarinic for overactive bladder. [2005.05]
A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. [2005.05]
Other possibly related research studies
New developments in the treatment of urinary incontinente. [2006.12]
[Anticholinergics for overactive bladder: does subtype selectivity play a role?] [2006.07]
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. [2006.03]
Newer agents for the management of overactive bladder. [2006.12.15]
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. [2006.12]
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. [2006.10.18]
Gateways to clinical trials. [2006.07]
Gateways to clinical trials. [2006.04]
[Oral anticholinergics in overactive bladder] [2006.07]
Practical considerations of new drugs: new choices for old problems. [2006.04]
Gateways to clinical trials. [2006.03]
Gateways to clinical trials. [2006.01]
Management of overactive bladder and urge urinary incontinence in the elderly patient. [2006.03]
Muscarinic receptors in the bladder: from basic research to therapeutics. [2006.02]
Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. [2006.01]
Solifenacin in overactive bladder syndrome. [2005]
Overactive bladder in the elderly: a guide to pharmacological management. [2005]
Gateways to clinical trials. [2005.10]
Gateways to clinical trials. [2005.09]
The Q-T interval and antimuscarinic drugs. [2005.11]
Solifenacin in the management of the overactive bladder syndrome. [2005.10]
Role of muscarinic receptor antagonists in urgency and nocturia. [2005.09]
Gateways to clinical trials. [2005.06]
Contemporary and emerging drug treatments for urinary incontinence in children. [2005]
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. [2005]
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. [2007.01]
Gateways to clinical trials. [2006.10]
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? [2006.11]
Overactive bladder treatments in early phase clinical trials. [2007.07]
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. [2007.05]
Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? [2007.06]
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. [2007.02.28]
[Treatment of overactive bladder in elderly and old people] [2007.04]
[How do medications used to treat urinary incontinence affect the cerebral function of the elderly?] [2007.04]
Muscarinic receptor antagonists for overactive bladder. [2007.11]
Pharmacologic management of overactive bladder. [2007]
Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. [2007.10.31]
Urgency in overactive bladder: Translating experimental data into clinical practice. [2008.05]
Gateways to clinical trials. [2008.01]
[Anticholinergic drugs in overactive bladder] [2008.01]
Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay. [2008.01]
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. [2008.09]
A journey to continence: a case study of overactive bladder syndrome. [2008.06]
Gateways to clinical trials. [2008.03]
Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. [2008.06]
[Anticholinergic treatment of overactive bladder syndrome : Is it all the same?] [2009.01.16]
Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). [2008.11.24]
Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. [2008.06]
Use of antimuscarinics in the elderly. [2009.06.12]
Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. [2009.03.01]
[Anticholinergic treatment of overactive bladder syndrome. Is it all the same?] [2009.03]
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? [2009.01]
Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). [2009]
Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. [2010.07.02]
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. [2010]
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [2010.08]
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study. [2009.11]
Enhanced sensitivity to afferent stimulation and impact of overactive bladder therapies in the conscious, spontaneously hypertensive rat. [2011.07]
Antimuscarinics suppress adenosine triphosphate and prostaglandin E2 release from urothelium with potential improvement in detrusor overactivity in rats with cerebral infarction. [2011.06]
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. [2011.08]
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. [2011.02.23]
|